The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing. Third, considerations should be given to treat selected patients with heart failure and preserved systolic function with a mineralocorticoid receptor antagonist and to treat patients with heart failure and reduced ejection fraction with an angiotensin receptor/neprilysin inhibitor, when the drug is approved. As with updates in previous years, the topics were chosen in response to stakeholder feedback. The 2014 Update includes recommendations, values and preferences, and practical tips to assist the clinicians and health care workers to best manage patients with heart failure.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Can J Cardiol

Title: The Canadian journal of cardiology

ISSN (Electronic): 1916-7075

ISSN (Print): 0828-282X

Publication date (Electronic): Jan 2015

Volume: 31

Issue: 1

Affiliations

[1 ] St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: moeg@smh.ca.

[2 ] University of Alberta, Edmonton, Alberta, Canada.

[3 ] Institut de Cardiologie de Montréal, Montreal, Québec, Canada.

[4 ] Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.

[5 ] University of Calgary, Calgary, Alberta, Canada.

[6 ] Sunnybrook Health Science Centre, Toronto, Ontario, Canada.

[7 ] St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

[8 ] University of Waterloo, Waterloo, Ontario, Canada.

[9 ] University Health Network, University of Toronto, Toronto, Ontario, Canada.

[10 ] St Boniface General Hospital, Cardiac Sciences Program, Winnipeg, Manitoba, Canada.

[11 ] Joseph Brant Memorial Hospital, Burlington, Ontario, Canada; Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.

[12 ] Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.

[13 ] QE II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.

[14 ] Royal Jubilee Hospital, Victoria, British Columbia, Canada.

[15 ] University of British Columbia, Vancouver, British Columbia, Canada.

[16 ] University of Western Ontario, London, Ontario, Canada.

[17 ] Penticton, British Columbia, Canada.

[18 ] Université de Moncton, Moncton, New Brunswick, Canada.

[19 ] Edmonton Cardiology Consultants, Edmonton, Alberta, Canada.

[20 ] Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada.

[21 ] McGill University, Montreal, Québec, Canada.

[22 ] Ottawa Heart Institute, Ottawa, Ontario, Canada.

[23 ] Centre Hospitalier Régional de Lanaudière, Joliette, Québec and Université Laval, Québec, Canada.

[24 ] Hôpital Laval, Sainte-Foy, Québec, Canada.

[25 ] Health Sciences Centre, St John's, Newfoundland, Canada.

Article

Publisher Item ID: S0828-282X(14)01492-5

DOI: 10.1016/j.cjca.2014.10.022

PubMed ID: 25532421

SO-VID: eafa2de7-034c-40c4-8281-60d3410beb17

History

Data availability:

Comments

Comment on this article

scite_

Cited by 24

See all cited by

- Version 1